Stay updated on Nivolumab and Cyclophosphamide for R/R AML Clinical Trial

Sign up to get notified when there's something new on the Nivolumab and Cyclophosphamide for R/R AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab and Cyclophosphamide for R/R AML Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now displays revision v3.8.0 instead of v3.7.2. The study record still shows a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T21:02:51.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    A notice about NIH websites transitioning from “Artificial Intelligence” to “Super Intelligence” appears above the page content.
    Difference
    1%
    Check dated 2026-10-24T22:11:04.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    The footer revision identifier was updated from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T21:00:35.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    The footer’s site revision indicator changes from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-10T21:48:44.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    Access to the study record is now blocked by a 403 Forbidden error page, replacing the study details and navigation. This indicates an error state rather than an actual content update.
    Difference
    19%
    Check dated 2026-09-19T20:21:20.000Z thumbnail image
  6. Check
    65 days ago
    Change Detected
    Summary
    Revision: v3.6.6 appears on the page, replacing v3.6.5. This indicates a minor update to page metadata or formatting without altering the study details, eligibility criteria, or outcomes.
    Difference
    0.1%
    Check dated 2026-08-29T20:48:43.000Z thumbnail image

Stay in the know with updates to Nivolumab and Cyclophosphamide for R/R AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab and Cyclophosphamide for R/R AML Clinical Trial page.